Revolutionizing Cancer Treatment with Ivonescimab
Summit Therapeutics
"Summit provides leadership with proven success in oncology development, regulatory approvals, and commercialization."
Bob Duggan
Chief Executive Officer
At the heart of Summit Therapeutics’ work is a powerful mission: to build a sustainable healthcare organization devoted to creating transformative medicines designed to improve quality of life, increase life duration, and address serious healthcare needs. This ambitious goal is underpinned by an exceptional blend of scientific and administrative expertise, as well as a clear focus on developing rapid, cost-efficient products, and engaging commercial partners when necessary.
A shining example of their ongoing mission is Ivonescimab, a novel drug designed to address the critical health issue of cancer. What makes Ivonescimab unique is that it combines two major anti-cancer actions into one single molecule – stimulating the immune system to fight cancer and inhibiting the formation of blood vessels that support tumor growth. This dual-action approach could potentially be a game-changer in cancer treatment.
Summit Therapeutics is currently focusing on applying Ivonescimab to treat a type of lung cancer known as NSCLC. If all goes according to plan, the company expects to start clinical trials by the middle of 2023, marking an important milestone in its mission to resolve serious healthcare needs.
In terms of global recognition, Ivonescimab has already made a significant impact. It received the “Breakthrough Therapy Designation” in China, a status reserved for promising drugs, for three different applications. This acknowledgment bolsters confidence in the potential effectiveness of Ivonescimab.
Moreover, the drug is undergoing trials in China and Australia for the treatment of various solid tumors. This includes a substantial Phase III clinical trial focusing on patients with NSCLC carrying an EGFR mutation and who have not responded to previous treatments.
The ethos of Summit Therapeutics extends beyond the development of new therapies. The team is committed to shouldering the full responsibility of successful design, development, regulatory approval, and commercialization. They constantly strive to expand their knowledge, capabilities, and wellbeing for all stakeholders and shareholders involved.
Founded in 2003, Summit Therapeutics is listed on the Nasdaq Global Market under the symbol ‘SMMT.’ The company is based in Menlo Park, California, with additional offices in Oxford, UK. With its forward-thinking approach and commitment to revolutionary healthcare solutions like Ivonescimab, Summit Therapeutics is undoubtedly setting new standards in the battle against cancer.
Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023
04 Jun 2023
Go to linkSummit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)
09 May 2023
Go to linkSummit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody
20 Jan 2023
Go to linkSummit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
05 Jan 2023
Go to linkSummit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody
12 Jun 2022
Go to linkSummit appoints Robert W. Duggan as Chief Executive Officer
14 Apr 2020
Go to linkSummit Therapeutics gets US$50mln backing from biotech billionaire Bob Duggan
06 Dec 2019
Go to linkEffect of broad vs. narrow-spectrum Clostridioides Difficile treatment on human stool bile acid composition over time
07 Oct 2019
Go to linkNarrow-spectrum antibiotic treatment of Clostridium Difficile infection improves preservation of intestinal metabolic profile
07 Oct 2019
Go to linkQuality of life changes in patients with Clostridium Difficile Infection (CDI): a Randomized, Double-blind Trial of Ridinilazole (RDZ) compared to Vancomycin (VAN)
03 Oct 2019
Go to linkCombating resistance while maintaining innovation: the future of anti-microbial stewardship
18 Sep 2019
Go to linkIn vivo proof of concept for a novel small molecule inhibitor of bacterial Lipoprotein transport targeting Enterobacteriaceae
05 Sep 2019
Go to linkFrom new mechanisms to new standards of care
24 Jun 2019
Go to linkNovel small-molecule inhibitors of bacterial Lipoprotein transport with potent antimicrobial activity against Enterobacteriaceae
14 Apr 2019
Go to linkRobert Duggan invests $25mn into Summit
17 Dec 2018
Go to linkA novel small molecule antibiotic for the treatment of Neisseria gonorrhoeae
13 Nov 2018
Go to linkRidinilazole for Clostridium Difficile Infection: human gut microbiome profiles from a phase 2 clinical trial
03 Oct 2018
Go to linkSummit Therapeutics was founded
01 Jan 2003
Go to linkSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023
11 May 2023
Go to linkSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022
04 Mar 2023
Go to linkSummit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering
03 Mar 2023
Go to linkSummit Therapeutics Inc. Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2022
09 Nov 2022
Go to linkSummit Therapeutics Inc. Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2022
09 Nov 2022
Go to linkReports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2020
29 Sep 2020
Go to linkSummit announces effectiveness of scheme of arrangement and completion of redomiciliation to Delaware, USA
18 Sep 2020
Go to linkSummit Therapeutics announces U.K. court approval for redomiciliation to Delaware, USA
17 Sep 2020
Go to linkRidinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids
29 Jul 2020
Go to linkPharmacyclics billionaire Bob Duggan takes the helm of another biotech — and he faces an even bigger uphill climb this time
14 Apr 2020
Go to linkBillionaire Robert Duggan’s New Biotech Chapter: An Antibiotics Quest
27 Feb 2020
Go to linkSummit Therapeutics appoints controlling shareholder, biotech billionaire Bob Duggan as its executive chairman
26 Feb 2020
Go to linkSummit Therapeutics announces £38M fundraising success
02 Jan 2020
Go to linkSummit Therapeutics’ Glyn Edwards talks about US$50mln backing and Ridinilazole progress
09 Dec 2019
Play VideoBillionaire’s big investment shows renewed faith in drugs company
07 Dec 2019
Go to linkSummit Therapeutics gets US$50mln backing from biotech billionaire Bob Duggan
06 Dec 2019
Go to linkBiotech firms fight panic over spread of superbugs
08 Nov 2019
Go to linkSummit Therapeutics to participate in panel sessions at the World Antimicrobial Resistance Congress.
06 Nov 2019
Go to linkSummit Therapeutics recognises C Difficile awareness month
04 Nov 2019
Go to linkSummit Therapeutics CEO says anti microbial resistance will be as big a problem as climate change
25 Oct 2019
Go to linkCan the rally in Summit Therapeutics shares continue?
22 Oct 2019
Go to linkSummit Therapeutics shares rise on phase II c.difficile data
03 Oct 2019
Go to linkSummit announces publication of editorial in future microbiology advocating for innovation in antibiotic development to drive stewardship focus on improving patient outcomes
17 Sep 2019
Go to linkSummit Therapeutics well placed in the race to find next-generation antibiotic
17 Apr 2019
Go to linkSummit presents in vivo proof of concept data for new mechanism antibiotics targeting Enterobacteriaceae in oral session at ECCMID 2019
14 Apr 2019
Go to linkSummit Therapeutics expands drug pipeline with antibiotics targeting deadly bacteria
04 Apr 2019
Go to linkSummit’s SMT-571 potent against over 200 clinical isolates of Neisseria Gonorrhoeae, including numerous multi- and extensively-drug resistant strains, in published preclinical data
25 Feb 2019
Go to linkSummit Therapeutics to present at the BIO CEO & Investor Conference
08 Feb 2019
Go to linkPrecision antibiotic improves outcome of gut infections in phase II
03 Aug 2018
Go to linkUS billionaire Robert Duggan to invest US$25mln into Summit Therapeutics
10 Jul 2018
Go to linkCambridge biotech Summit pivots from failed trial, layoffs with $4.5M from CARB-X
10 Jul 2018
Go to linkDisappointment for Summit Therapeutics as rare disease drug flops in trials
27 Jun 2018
Go to linkSummit confirms £10mln acquisition of antibiotics discovery group Discuva
27 Dec 2017
Go to link"Certainly a resident tendency to expect the best possible outcome fuels the energy always required to make a meaningful difference for the betterment of existing conditions.”
Bob Duggan
Chief Executive Officer
Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023
04 Jun 2023
Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)
09 May 2023
Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody
20 Jan 2023
Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
05 Jan 2023
Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody
12 Jun 2022
Summit appoints Robert W. Duggan as Chief Executive Officer
14 Apr 2020
Summit Therapeutics gets US$50mln backing from biotech billionaire Bob Duggan
06 Dec 2019
Effect of broad vs. narrow-spectrum Clostridioides Difficile treatment on human stool bile acid composition over time
07 Oct 2019
Narrow-spectrum antibiotic treatment of Clostridium Difficile infection improves preservation of intestinal metabolic profile
07 Oct 2019
Quality of life changes in patients with Clostridium Difficile Infection (CDI): a Randomized, Double-blind Trial of Ridinilazole (RDZ) compared to Vancomycin (VAN)
03 Oct 2019
Combating resistance while maintaining innovation: the future of anti-microbial stewardship
18 Sep 2019
In vivo proof of concept for a novel small molecule inhibitor of bacterial Lipoprotein transport targeting Enterobacteriaceae
05 Sep 2019
From new mechanisms to new standards of care
24 Jun 2019
Novel small-molecule inhibitors of bacterial Lipoprotein transport with potent antimicrobial activity against Enterobacteriaceae
14 Apr 2019
Robert Duggan invests $25mn into Summit
17 Dec 2018
A novel small molecule antibiotic for the treatment of Neisseria gonorrhoeae
13 Nov 2018
Ridinilazole for Clostridium Difficile Infection: human gut microbiome profiles from a phase 2 clinical trial
03 Oct 2018
Summit Therapeutics was founded
01 Jan 2003
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023
11 May 2023
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022
04 Mar 2023
Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering
03 Mar 2023
Summit Therapeutics Inc. Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2022
09 Nov 2022
Summit Therapeutics Inc. Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2022
09 Nov 2022
Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2020
29 Sep 2020
Summit announces effectiveness of scheme of arrangement and completion of redomiciliation to Delaware, USA
18 Sep 2020
Summit Therapeutics announces U.K. court approval for redomiciliation to Delaware, USA
17 Sep 2020
Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids
29 Jul 2020
Pharmacyclics billionaire Bob Duggan takes the helm of another biotech — and he faces an even bigger uphill climb this time
14 Apr 2020
Billionaire Robert Duggan’s New Biotech Chapter: An Antibiotics Quest
27 Feb 2020
Summit Therapeutics appoints controlling shareholder, biotech billionaire Bob Duggan as its executive chairman
26 Feb 2020
Summit Therapeutics announces £38M fundraising success
02 Jan 2020
Summit Therapeutics’ Glyn Edwards talks about US$50mln backing and Ridinilazole progress
09 Dec 2019
Billionaire’s big investment shows renewed faith in drugs company
07 Dec 2019
Summit Therapeutics gets US$50mln backing from biotech billionaire Bob Duggan
06 Dec 2019
Biotech firms fight panic over spread of superbugs
08 Nov 2019
Summit Therapeutics to participate in panel sessions at the World Antimicrobial Resistance Congress.
06 Nov 2019
Summit Therapeutics recognises C Difficile awareness month
04 Nov 2019
Summit Therapeutics CEO says anti microbial resistance will be as big a problem as climate change
25 Oct 2019
Can the rally in Summit Therapeutics shares continue?
22 Oct 2019
Summit Therapeutics shares rise on phase II c.difficile data
03 Oct 2019
Summit announces publication of editorial in future microbiology advocating for innovation in antibiotic development to drive stewardship focus on improving patient outcomes
17 Sep 2019
Summit Therapeutics well placed in the race to find next-generation antibiotic
17 Apr 2019
Summit presents in vivo proof of concept data for new mechanism antibiotics targeting Enterobacteriaceae in oral session at ECCMID 2019
14 Apr 2019
Summit Therapeutics expands drug pipeline with antibiotics targeting deadly bacteria
04 Apr 2019
Summit’s SMT-571 potent against over 200 clinical isolates of Neisseria Gonorrhoeae, including numerous multi- and extensively-drug resistant strains, in published preclinical data
25 Feb 2019
Summit Therapeutics to present at the BIO CEO & Investor Conference
08 Feb 2019
Precision antibiotic improves outcome of gut infections in phase II
03 Aug 2018
US billionaire Robert Duggan to invest US$25mln into Summit Therapeutics
10 Jul 2018
Cambridge biotech Summit pivots from failed trial, layoffs with $4.5M from CARB-X
10 Jul 2018
Disappointment for Summit Therapeutics as rare disease drug flops in trials
27 Jun 2018
Summit confirms £10mln acquisition of antibiotics discovery group Discuva
27 Dec 2017
Summit Therapeutics
Pulse Biosciences
Human Longevity Inc
Pharmacyclics
Intuitive Surgical
Computer Motion
Metropolis Media
Communication Machinery Company
Government Technology Services
Paradise Bakery
Sunset Designs